TOMZ

TOMI Environmental Solutions, Inc. (TOMZ) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. TOMI Environmental Solutions, Inc. is a global provider of disinfection and decontamination solutions utilizing patented Binary Ionization Technology (BIT). The company operates as a single reportable segment serving Life Sciences, Hospital-Healthcare, Food Safety, and Commercial markets. As of April 29, 2026, there were 21,700,465 shares of common stock outstanding.

Key Financial Metrics

Liquidity: Net cash provided by operating activities was $295,551, a significant improvement from a use of $275,698 in the prior year period. However, financing activities resulted in a net cash outflow of $97,569 due to repayments on the sale of future receipts agreement.

Material Changes vs. Prior Period

• Revenue Mix Shift: Product revenue increased 31% to $1.31 million, driven by equipment and Custom Engineered System (CES) sales. Conversely, Service revenue declined 41% to $343,000 due to project timing.
• Margin Compression: Gross margin decreased from 60% to 50%. Management attributes this to strategic price discounts to drive equipment adoption and a shift toward lower-margin equipment sales.
• Operating Expense Reduction: Total operating expenses decreased by $248,000 (15%), primarily due to reductions in General and Administrative expenses ($136,000 decrease) and Selling expenses ($49,000 decrease).
• Net Loss Expansion: The net loss widened significantly to $810,645 compared to $255,593 in Q1 2025. This was largely driven by the absence of a one-time $535,000 Employee Retention Credit benefit recognized in the prior year and increased interest expense ($65,000 increase) due to higher debt balances.

Outlook, Risks, and Contingencies

• Going Concern: The filing explicitly states that the company's accumulated deficit of $58.9 million, recurring losses, and limited working capital raise substantial doubt about its ability to continue as a going concern within one year. Management's plan relies on the $20 million Equity Line of Credit (ELOC) with Hudson Global Ventures, pipeline conversion, and cost management.
• Pipeline and Backlog: The integrated project pipeline stands at approximately $4.3 million across 13 customers. Sales backlog is approximately $1.7 million. A $440,000 annual recurring service order was secured with a global medical technology company.
• Proposed Merger: On April 30, 2026 (subsequent event), TOMI executed a non-binding Letter of Intent to merge with Carbonium Core, Inc. The transaction implies a $120 million enterprise valuation for Carbonium Core and would result in a change of control. Completion is not guaranteed.
• Nasdaq Compliance: The company is subject to two concurrent deficiency proceedings regarding minimum bid price ($1.00) and minimum stockholders' equity ($2.5 million). Failure to regain compliance by May 18, 2026, could result in delisting.
• Internal Controls: Management identified a material weakness in internal control over financial reporting related to limited resources and ineffective review procedures, which remains unremediated as of March 31, 2026.

Investor Verification Checklist

• Capital Adequacy: Verify the status of the $20 million ELOC with Hudson Global and the company's ability to draw down funds given current market conditions.
• Merger Viability: Assess the likelihood of the Carbonium Core merger closing, given the non-binding nature of the LOI and the requirement for stockholder approval.
• Nasdaq Status: Monitor the company's progress in regaining compliance with Nasdaq listing standards (bid price and equity) by the May 18, 2026 deadline.
• Debt Obligations: Review the terms of the $3.1 million convertible notes (12% interest) and the Agile Capital sale of future receipts to understand immediate cash flow pressures.
• Margin Recovery: Evaluate whether the shift to high-margin consumable sales (BIT Solution) is sufficient to offset the lower margins from equipment sales in future quarters.